Nasus Pharma has reported positive preclinical pharmacokinetic and safety data for NS003, its intranasal powder formulation of ondansetron, with results indicating bioavailability comparable to intravenous administration in an animal model. The findings position the program for advancement into a first-in-human PK study targeted for the third quarter of 2026.
The preclinical data are notable from a delivery-science standpoint: achieving IV-comparable pharmacokinetic profiles via a nasal powder formulation requires overcoming significant mucosal absorption barriers, including enzymatic degradation and mucociliary clearance. Ondansetron, a 5-HT3 receptor antagonist widely used as an antiemetic, has historically required intravenous or oral administration, with oral bioavailability limited by hepatic first-pass metabolism. A validated intranasal route could meaningfully alter the absorption curve and time-to-peak plasma concentration — two clinical endpoints critical for acute nausea management.
While NS003 is a pharmaceutical-track asset rather than a finished dietary supplement formulation, the delivery platform has downstream relevance for the functional foods and nutraceutical channel. Intranasal bioavailability research increasingly informs how ingredient suppliers and contract formulators approach difficult-to-absorb actives — from magnesium glycinate to liposomal B12 — where first-pass metabolism erodes efficacy. Operators developing condition-specific wellness SKUs targeting nausea, motion sickness, or chemotherapy support are watching non-oral delivery innovations closely as a potential white-label or co-manufacturing differentiator. The global antiemetic market was valued at several billion dollars as of recent estimates, with OTC and functional wellness segments drawing increased consumer interest post-pandemic.
Nasus Pharma has not disclosed partnership or licensing terms at this stage, and no structure-function claims have been filed for NS003 under current regulatory frameworks. The first-in-human study will generate the human PK data necessary to assess whether preclinical absorption findings translate — a standard and critical inflection point before any commercial or formulation discussions become actionable. Functional ingredient developers tracking novel delivery mechanisms, particularly those working in the nootropic and cognitive wellness space or the sports nutrition and recovery category, should note the timeline for human-phase readouts in late 2026.
For broader context on delivery innovation trends shaping the nutraceutical supply chain, Food & Beverage Magazine has covered the acceleration of non-oral formats across both pharmaceutical and functional categories. As ingredient suppliers compete on bioavailability differentiation, preclinical platforms like NS003 serve as early signals of where delivery science is headed — even when the immediate application sits outside the dietary supplement regulatory lane.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.